In conclusion, our analysis of FGFR2 signalling and the effect of breast cancer risk variants suggest that the role of FGFR2 germline variants in breast cancer risk may be linked to reducing a cell’s ability to respond to oestrogen activation. This evidence concerns the gene FGFR2 and breast carcinoma.